Imjudo (Tremelimumab)

Tremelimumab binds to the CTLA‑4 receptor on activated T‑cells, preventing the receptor from delivering an inhibitory signal. This blockade releases the brake on T‑cell activation, leading to increased proliferation, cytokine production, and cytotoxic activity against cancer cells. By enhancing the immune system’s ability to recognize and destroy tumor cells, it contributes to antitumor effects.

The dosing regimen for Imjudo is determined by the treating physician based on the patient’s clinical condition, body weight, and treatment protocol. It is administered as an intravenous infusion at intervals specified in the approved label or clinical trial guidelines. Patients should follow the prescriber’s instructions and the infusion schedule set by their oncology team.

Safety data for tremelimumab in pregnant or nursing individuals are limited. Because the drug modulates the immune system, it may pose risks to the fetus or infant. Use during pregnancy or lactation is generally avoided unless the potential benefit justifies the potential risk, and decisions should be made in consultation with a specialist.

To request Imjudo, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a quotation, confirming availability, arranging cold‑chain shipping if needed, and handling all necessary import documentation.

Imjudo targets CTLA‑4, whereas many other approved checkpoint inhibitors such as pembrolizumab or nivolumab target the PD‑1 pathway. CTLA‑4 blockade tends to produce a broader activation of T‑cells but may be associated with a higher incidence of immune‑related adverse events. Combination therapy with PD‑L1 inhibitors like durvalumab can provide synergistic antitumor activity, offering an alternative to PD‑1 monotherapy in certain melanoma cases.

Imjudo must be stored refrigerated at 2 °C to 8 °C. The solution should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to infusion, the product may be allowed to reach room temperature as directed, but any deviation from the recommended conditions can affect stability and potency.

Imjudo is supplied as a sterile solution for infusion and is given by intravenous infusion under the supervision of qualified healthcare professionals. The infusion is typically administered over a set period, often ranging from 30 to 60 minutes, depending on the protocol. Patients are monitored during and after the infusion for any immediate adverse reactions.

The most serious risks of tremelimumab involve immune‑mediated toxicities such as colitis, hepatitis, severe endocrinopathies (including hypophysitis and thyroiditis), pneumonitis, myocarditis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Early detection and prompt management with immunosuppressive therapy are critical to mitigate these potentially severe complications.

Imjudo is contraindicated in patients with active autoimmune diseases that require systemic immunosuppression, those receiving live or attenuated vaccines, and individuals who have experienced severe hypersensitivity to tremelimumab or any of its excipients. Caution is also advised for organ transplant recipients and patients with uncontrolled infections, as the drug’s immune‑activating effects may exacerbate these conditions.